Bryan A. Cotton, James J McCarthy, John B. Holcomb
Abstract
The new oral direct thrombin inhibitor, dabigatran, is proving to be problematic in acutely injured patients, since it may promote bleeding and its effect cannot be easily reversed.
OpenAlex reports 161 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The new oral direct thrombin inhibitor, dabigatran, is proving to be problematic in acutely injured patients, since it may promote bleeding and its effect cannot be easily reversed.
Key concepts: Dabigatran, Medicine, Direct thrombin inhibitor, Antithrombins, Thrombin, Prothrombin complex concentrate, Anesthesia, Intensive care medicine